ExpreS2ion Biotechnologies is a world leading contract research organisation (CRO) within production in Drosophila Schneider-2 (S2) cells.

For 15 years we have developed, and actively used our proprietary and complete S2 recombinant protein technology ExpreS2.

We have in-depth practical experience with this non-viral Drosophila S2 expression technology for the production of recombinant proteins for research, preclinical development and for use in clinical trials.

Our solutions:

Products

Services

Customers and collaborating partners

spacer

About

ExpreS2ion Biotechnologies is a world leading CRO biotech company

Our company has a proprietary and complete S2 recombinant protein technology base – ExpreS2, which was developed over ten years at Pharmexa A/S. We have in-depth practical experience with the non-viral Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials.

Contribution to Malaria Vaccines/Research

By leveraging our ability to express malaria parasite proteins with ExpreS2 a cGMP-compatible system, we have enabled progress of malaria vaccine candidates into clinical research. ExpreS2ion Biotechnologies is working with top academic teams to advance vaccines directed at different malaria stages of infection: blood stage malaria and pregnancy malaria.

Solutions

Services, Custom Proteins

“Challenging proteins made easy”

The ExpreS2 system, based on Drosophila S2 cell expression can solve your “protein dead-ends” by providing an alternative, cGMP-compatible expression system.
When to choose the S2 expression system:

  • Secreted or secretable proteins
  • Low/non-expressing proteins in HEK293 or BEVS
  • Issues with protein cleavage during production
  • Heterodimers or further multimeric proteins
  • If variable glycosylation is an issue
  • If you need a cGMP-compatible system

ExpreS2ion Biotechnologies specializes in establishment of high-producing cell lines together with upstream process development and working with customers to solve technical problems in molecular biology, protein expression or other issues relating to S2 cells. S2 related reagents are also available.

NEWS

Latest news

March 2015 : A vaccine against placental malaria made with ExpreS2ion® Biotechnologies’ protein expression technology, ExpreS2, is ready to start human tests in Germany and Benin. Read the PR

February 2015 : ExpreS2ion® Biotechnologies licenses the ExpreS2 system to the Gene Center in Munich, Germany: Scientists at the Gene Center in Munich are using the ExpreS2 protein production system to address expression of antibody fragment and other “challenging to express” proteins, in their research efforts to understand how cells detect damaged DNA and viral RNA. Read the PR

January 2015 : ExpreS2ion® Biotechnologies mentioned in Animal Pharm’s Weekly Briefing

Publications
  • "Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA" by using the ExpreS2 technology platform: PLoS One. 2014; 9(1): e84981. PMCID: PMC3897377 Read the article here

  • "Advances in the Application of Perfusion Technologies to Drosophila S2 Insect Cell Culture" Lars Poulsen and Willem A. de Jongh, pp 165-182. Continuous Processing in Pharmaceutical Manufacturing, First Edition. Edited by Ganapathy Subramanian. December 2014 Wiley VCH. ISBN: 978-3-527-33595-4 Find out more here

  • "Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies" enabled by the ExpreS2 technology platform: Nature (17 August 2014), doi:10.1038/nature13715 Read the abstract here

  • ExpreS2ion Biotechnologies: Agern Allé 1, DK-2970 Horsholm, Denmark E-mail: info@expres2ionbio.com Phone: +45 4166 6121